TEMPUS PHOENIX HNSCC STUDY A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head Neck Squamous Cell Carcinoma HNSCC

What this Trial Is About

Researchers are conducting a prospective, longitudinal, non-interventional study involving participants with metastatic or unresectable recurrent head and neck squamous cell carcinoma HNSCC. The study focuses on molecular biomarker profiling using tissue and blood samples collected during participants standard care treatment, aiming to enhance understanding of prognostic and predictive biomarkers over a five-year period. Participants planned for first-line immunotherapy or combination therapy will be included, with no additional interventions applied by the study. Up to 500 participants with tumors located in the pharynx, larynx, oral cavity, or oropharynx will be observed. Tissue samples representative of current disease and longitudinal blood samples will be collected to analyze DNA, RNA, immune, and other multiomic biomarkers. Throughout the study, participants will undergo biomarker assessments from blood and tumor tissue collected at diagnosis and progression. Researchers will explore changes in circulating tumor DNA ctDNA and other biomarkers to understand treatment responses and resistance mechanisms. The study will last up to five years, focusing on real-world outcomes and biomarker evolution during routine care without altering treatment plans.

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)